Drug Profile


Alternative Names: IQB 875; IQB 875D

Latest Information Update: 11 Nov 1998

Price : $50

At a glance

  • Originator IQB
  • Developer Almirall-Prodesfarma; IQB
  • Class Antihypertensives; Dihydropyridines; Ischaemic heart disorder therapies
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Angina pectoris; Atherosclerosis; Coronary disorders; Essential hypertension; Heart failure

Most Recent Events

  • 11 Nov 1998 Discontinued-Clinical for Essential hypertension (IV)
  • 11 Nov 1998 Discontinued-Preclinical for Congestive heart failure (Unknown route)
  • 11 Nov 1998 Discontinued-Preclinical for Coronary disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top